Dapagliflozin and Foot Ulcers: Amputation Risk Explained
Dapagliflozin carries an amputation-risk signal seen with canagliflozin; learn screening steps, lower-limb monitoring, and when to hold SGLT2 therapy.
Sglt2 Inhibitors: Drug Class Monograph
6 source-based articles maintained by the HealthRX.com Editorial Team.
6articles
4topic areas covered
Jul 10, 2025latest review
Sglt2 Inhibitors: Drug Class Monograph library
Showing 6 of 6 clinical reviews.
Dapagliflozin Monitoring Requirements: Baseline, Ongoing Checks
Dapagliflozin monitoring needs baseline eGFR and urinalysis, interim volume and infection checks, and a stopping protocol for DKA, surgery, or eGFR decline.
SGLT2 Inhibitor Brands Compared by Ease of Use
Empagliflozin and dapagliflozin offer broadest labels and simplest dosing; canagliflozin fits CKD niche; sotagliflozin adds SGLT1 for heart failure.
SGLT2 Inhibitors Billing & Prior-Auth Playbook
A complete MD/PharmD-level guide to SGLT2 inhibitor billing codes, prior-authorization requirements, step-therapy rules, and appeals strategy for empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin.
SGLT2 Inhibitors Drug-Drug Interaction Table
Clinician-facing SGLT2 inhibitor DDI reference table covering empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin with insulin, diuretics, lithium, digoxin, and more.
SGLT2 Inhibitors Special Populations Summary
A prescriber-level summary of SGLT2 inhibitor use across special populations: heart failure, CKD, elderly patients, pregnancy, and more. Includes trial data, dosing guidance, and safety considerations.